Nitto Denko

Pacesetter of Sylmar, Calif., has received US Patent No.

Title: Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis
Patent Number: 8,178,124
Filed: Sept. 29, 2011
Lead Inventor: Yoshiro Niitsu, Nitto Denko

The deal follows Nitto Denko's establishment of an siRNA drug-development deal with Quark Pharmaceuticals.

While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.

According to a company official, future deals, as with the one with Nitto Denko, will be driven by Quark's freedom to operate in the siRNA drugs space.

Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.

The partnership is expected to yield its first IND by 2012.

Pages

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.